Chitosan/Copaiba oleoresin films for would dressing application

[Display omitted] Biopolymeric films can be used as dressings for the treatment of skin burns and other chronic wounds. The healing properties of these films may be enhanced by the addition of Copaiba oil (Copaifera L.) which properties have already been well-described. The aim of this study was to...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics Vol. 555; pp. 146 - 152
Main Authors: Debone, Henrique Selli, Lopes, Patrícia Santos, Severino, Patrícia, Yoshida, Cristiana Maria Pedroso, Souto, Eliana B., da Silva, Classius Ferreira
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 30-01-2019
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Biopolymeric films can be used as dressings for the treatment of skin burns and other chronic wounds. The healing properties of these films may be enhanced by the addition of Copaiba oil (Copaifera L.) which properties have already been well-described. The aim of this study was to evaluate the addition of Copaiba oil in chitosan films prepared by casting solvent evaporation technique using chitosan solution (2% or 1% wt/wt) and Copaiba oil (0.1 or 1.0% wt/wt) at different concentrations. Films were characterized by color analysis, scanning electron microscopy, mechanical properties, thermal analysis, and fluid handling capacity. The developed films demonstrated potential for wound dressing, translated by the fluid handling capacity similar to that of commercial dressings. While no surfactant was present in the formulation, the droplets of Copaiba oil were well-dispersed and homogeneously distributed in the chitosan matrix even after drying. The thermal analysis translated the occurrence of interactions between the oil and chitosan.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2018.11.054